Alkermes plc. Debt Issuance Costs, Net
Alkermes plc. (ALKS) had Debt Issuance Costs, Net of $3.90 million as of 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Notes › Debt › Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
us-gaap:DeferredFinanceCostsNet · last filed 2026-07-28
- 2026-06-30: Debt Issuance Costs, Net $3.90M.
- 2026-03-31: Debt Issuance Costs, Net $4.30K.
- 2022-12-31: Debt Issuance Costs, Net $500.00K.
- 2021-12-31: Debt Issuance Costs, Net $600.00K.
| Period end | Debt Issuance Costs, Net |
|---|---|
| 2026-06-30 | $3.90M 10-Q · filed 2026-07-28 |
| 2026-03-31 | $4.30K 10-Q · filed 2026-05-05 |
| 2022-12-31 | $500.00K 10-K · filed 2023-02-16 |
| 2021-12-31 | $600.00K 10-K · filed 2022-02-16 |
| 2020-12-31 | $400.00K 10-K · filed 2021-02-11 |
| 2019-12-31 | $600.00K 10-K · filed 2020-02-13 |
| 2018-12-31 | $800.00K 10-K · filed 2019-02-15 |
| 2017-12-31 | $1.00M 10-K · filed 2018-02-16 |
| 2016-12-31 | $1.30M 10-K · filed 2017-02-17 |
| 2015-12-31 | $1.70M 10-K · filed 2016-02-25 |
| 2014-12-31 | $2.20M 10-K · filed 2015-02-24 |
| 2013-12-31 | $2.70M 10-KT · filed 2014-02-27 |
| 2013-03-31 | $3.30M 10-K · filed 2013-05-23 |
| 2012-12-31 | $4.50M 10-Q · filed 2013-01-31 |
| 2012-09-30 | $4.60M 10-Q · filed 2012-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |